Preparation and structural properties of selenium modified heteropolysaccharide from the fruits of Akebia quinata and in vitro and in vivo antitumor activity

A series of novel 2-chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives were designed and synthesized as antitumor agents under the combination principle. The antitumor activity and mechanisms were then evaluated.

Download Full-text

„IN VITRO“ AND „IN VIVO“ ANTITUMOR ACTIVITY OF PLATINUM(II) COMPLEXES WITH MALONIC ACID ON BREAST AND COLORECTAL CARCINOMA CELL LINES

10.46793/iccbi21.293f ◽

2021 ◽

Author(s):

Andjela Franich ◽

◽

Milica Dimitrijević Stojanović ◽

Snežana Rajković ◽

Marina Jovanović ◽

...

Keyword(s):

Antitumor Activity ◽

Colorectal Carcinoma ◽

Cell Lines ◽

Tumor Model ◽

Carcinoma Cells ◽

Spectroscopic Techniques ◽

Murine Cell Line ◽

In Vivo Antitumor Activity

Four Pt(II) complexes of the general formula [Pt(L)(5,6-epoxy-1,10-phen)], where L is anion of malonic (mal, Pt1), 2-methylmalonic (Me-mal, Pt2), 2,2-dimethylmalonic (Me2-mal, Pt3) or 1,1- cyclobutanedicarboxylic (CBDCA, Pt4) acid while 5,6-epoxy-1,10-phen is bidentately coordinated 5,6-epoxy-5,6-dihydro-1,10-phenanthroline were synthesized and characterized by elemental microanalysis, IR, UV-Vis and NMR (1H and 13C) spectroscopic techniques. In vitro anticancer activity of novel platinum(II) complexes have been investigated on human and murine cancer cell lines, as well as normal murine cell line by MTT assay. The obtained results indicate that studied platinum(II) complexes exhibited strong cytotoxic activity against murine breast carcinoma cells (4T1), human (HCT116) and murine (CT26) colorectal carcinoma cells. Complex Pt3 display stronger selectivity toward carcinoma cells in comparison to other tested platinum(II) complexes exhibiting beneficial antitumor activity mainly via the induction of apoptosis, as well as inhibition of cell proliferation and migration. Further study showed that Pt3 complex also carry significant in vivo antitumor activity in orthotopical 4T1 tumor model without detected liver, kidney, lung, and heart toxicity. All results imply that these novel platinum(II) complexes have a good anti-tumor effect on breast and colorectal cancer in vivo and in vitro and the affinity to become possible candidates for treatment in anticancer therapy.

Download Full-text

Cytotoxicity and Antitumor Activity of Platinum(II) Complexes of Aromatic and Cycloalkanecarboxylic Acid Hydrazides

Zeitschrift für Naturforschung C ◽

10.1515/znc-1997-1-209 ◽

1997 ◽

Vol 52 (1-2) ◽

pp. 49-54 ◽

Cited By ~ 7

Author(s):

Daniel N. Kushev ◽

Nadejda C. Spassovska ◽

Svetoslav I. Taxirov ◽

Konstantin C. Grancharov

Keyword(s):

Antitumor Activity ◽

Acid Hydrazide ◽

In Vitro Cytotoxicity ◽

Macromolecular Synthesis ◽

H Nmr ◽

Antineoplastic Effect ◽

In Vivo Antitumor Activity ◽

Friend Leukemia

AbstractNew platinum(II) complexes of cyclohexanecarboxylic acid hydrazide (chcah) were synthesized and characterized by elemental analysis, IR. and 1H NMR spectra. Their inhibitory effects on cell growth and macromolecular synthesis of Friend leukemia cells in culture as well as the in vivo antitumor activity towards L1210 leukemia in mice were compared with those of complexes containing differently substituted aromatic acid hydrazides. Some of the complexes exhibited antineoplastic activity. No correlation between the in vitro cytotoxicity and the in vivo antitumor activity was found. However, there was a relationship between the in vitro macromolecular synthesis inhibition profile and the in vivo antineoplastic effect, similar to that of cisplatin. On the other hand, only agents containing one ammine ligand were active in vivo. The substitution of the aromatic ring by a cycloalkane residue increased significantly the antitumor effect, with [Pt(NH3)(chcah)Cl2] being the most active compound in this study.

Download Full-text

In vitro and in vivo antitumor activity of deoxyelephantopin from a potential medicinal plant Elephantopus scaber against Ehrlich ascites carcinoma

Biocatalysis and Agricultural Biotechnology ◽

10.1016/j.bcab.2019.101106 ◽

2019 ◽

Vol 19 ◽

pp. 101106 ◽

Cited By ~ 1

Author(s):

Farha Arakkaveettil Kabeer ◽

Dhanya Sethumadhavan Rajalekshmi ◽

Mangalam Sivasankaran Nair ◽

Remani Prathapan

Keyword(s):

Antitumor Activity ◽

Medicinal Plant ◽

Ehrlich Ascites Carcinoma ◽

In Vivo Antitumor Activity ◽

Ehrlich Ascites ◽

Elephantopus Scaber

Download Full-text

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

Cells ◽

10.3390/cells9071592 ◽

2020 ◽

Vol 9 (7) ◽

pp. 1592

Author(s):

Surendra R. Punganuru ◽

Viswanath Arutla ◽

Wei Zhao ◽

Mehrdad Rajaei ◽

Hemantkumar Deokar ◽

...

Keyword(s):

Brain Tumor ◽

Antitumor Activity ◽

Cell Lines ◽

Tumor Therapy ◽

Single Agent ◽

M Cell ◽

In Vivo Antitumor Activity ◽

The Brain

There is a desperate need for novel and efficacious chemotherapeutic strategies for human brain cancers. There are abundant molecular alterations along the p53 and MDM2 pathways in human glioma, which play critical roles in drug resistance. The present study was designed to evaluate the in vitro and in vivo antitumor activity of a novel brain-penetrating small molecule MDM2 degrader, termed SP-141. In a panel of nine human glioblastoma and medulloblastoma cell lines, SP-141, as a single agent, potently killed the brain tumor-derived cell lines with IC50 values ranging from 35.8 to 688.8 nM. Treatment with SP-141 resulted in diminished MDM2 and increased p53 and p21cip1 levels, G2/M cell cycle arrest, and marked apoptosis. In intracranial xenograft models of U87MG glioblastoma (wt p53) and DAOY medulloblastoma (mutant p53) expressing luciferase, treatment with SP-141 caused a significant 4- to 9-fold decrease in tumor growth in the absence of discernible toxicity. Further, combination treatment with a low dose of SP-141 (IC20) and temozolomide, a standard anti-glioma drug, led to synergistic cell killing (1.3- to 31-fold) in glioma cell lines, suggesting a novel means for overcoming temozolomide resistance. Considering that SP-141 can be taken up by the brain without the need for any special delivery, our results suggest that SP-141 should be further explored for the treatment of tumors of the central nervous system, regardless of the p53 status of the tumor.

Download Full-text